These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1967302)

  • 21. Comparison of brain tumor growth kinetics by proliferating cell nuclear antigen (PCNA) and bromodeoxyuridine (BrdU) labeling.
    Lee KS; Yang WI
    Yonsei Med J; 1992 Sep; 33(3):265-71. PubMed ID: 1363339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical expression of proliferating cell nuclear antigen (PCNA) in intracranial glioma and meningioma.
    Shih YH; Kadota Y; Sato K; Sueyoshi N; Shirai T
    Zhonghua Yi Xue Za Zhi (Taipei); 1994 Apr; 53(4):193-7. PubMed ID: 7911730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histochemical study of pituitary adenomas with Ki-67 and anti-DNA polymerase alpha monoclonal antibodies, bromodeoxyuridine labeling, and nucleolar organizer region counts.
    Shibuya M; Saito F; Miwa T; Davis RL; Wilson CB; Hoshino T
    Acta Neuropathol; 1992; 84(2):178-83. PubMed ID: 1381860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Embedding and fixation techniques for immunohistochemical staining with anti-DNA polymerase alpha and Ki-67 monoclonal antibodies to analyze the proliferative potential of tumors.
    Shibuya M; Miwa T; Hoshino T
    Biotech Histochem; 1992 May; 67(3):161-4. PubMed ID: 1377508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The proliferative cell fraction in cytology specimens. A study of human esophageal carcinoma.
    Sasano H; Miyazaki S; Nishihira T; Sawai T; Nagura H
    Am J Clin Pathol; 1992 Aug; 98(2):161-6. PubMed ID: 1354940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters.
    McKeever PE; Ross DA; Strawderman MS; Brunberg JA; Greenberg HS; Junck L
    J Neuropathol Exp Neurol; 1997 Jul; 56(7):798-805. PubMed ID: 9210876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proliferation markers Ki-67 and p105 in soft-tissue lesions. Correlation with DNA flow cytometric characteristics.
    Swanson SA; Brooks JJ
    Am J Pathol; 1990 Dec; 137(6):1491-500. PubMed ID: 1979714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cell kinetic analysis of brain tumors using the monoclonal antibody Ki-67: in vitro and in situ study.
    Shiraishi T
    Acta Med Okayama; 1990 Aug; 44(4):187-201. PubMed ID: 2244474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on proliferation-associated antibodies applicable to formalin-fixed paraffin-embedded tissue and their clinical applications.
    Yu CC; Filipe MI
    Histochem J; 1993 Dec; 25(12):843-53. PubMed ID: 7906685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell kinetics studies of human brain tumors by in vitro labeling using anti-BUdR monoclonal antibody.
    Nishizaki T; Orita T; Saiki M; Furutani Y; Aoki H
    J Neurosurg; 1988 Sep; 69(3):371-4. PubMed ID: 3404235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell-cycle analysis detecting endogenous nuclear antigens: comparison with BrdU-in vivo labeling and an application to lung tumors.
    Hayashi Y; Fukayama M; Koike M; Kaseda S; Ikeda T; Yokoyama T
    Acta Pathol Jpn; 1993 Jun; 43(6):313-9. PubMed ID: 8346708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Flow cytometric multiparameter analysis of proliferating cell nuclear antigen/cyclin and Ki-67 antigen: a new view of the cell cycle.
    Landberg G; Tan EM; Roos G
    Exp Cell Res; 1990 Mar; 187(1):111-8. PubMed ID: 1967582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of proliferative activities in human brain tumor specimens: a comparison of three methods.
    Morimura T; Kitz K; Stein H; Budka H
    J Neurooncol; 1991 Feb; 10(1):1-11. PubMed ID: 2022970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is Ki-67 a better proliferative marker in the colon than proliferating cell nuclear antigen?
    Holt PR; Moss SF; Kapetanakis AM; Petrotos A; Wang S
    Cancer Epidemiol Biomarkers Prev; 1997 Feb; 6(2):131-5. PubMed ID: 9037564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimization of immunohistochemical staining of proliferating cells in paraffin sections of breast carcinoma using antibodies to proliferating cell nuclear antigen and the Ki-67 antigen.
    Yu CC; Dublin EA; Camplejohn RS; Levison DA
    Anal Cell Pathol; 1995 Jul; 9(1):45-52. PubMed ID: 7577754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: a comparative study.
    Louis DN; Edgerton S; Thor AD; Hedley-Whyte ET
    Acta Neuropathol; 1991; 81(6):675-9. PubMed ID: 1679278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A review of cell kinetic studies on brain tumors with special reference to anti-bromodeoxyuridine monoclonal antibody method].
    Nagashima T; Hoshino T
    No Shinkei Geka; 1984 Aug; 12(9):1007-18. PubMed ID: 6390240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative flow cytometric analysis of Ki-67 and proliferating cell nuclear antigen (PCNA) in solid neoplasms.
    Steck K; el-Naggar AK
    Cytometry; 1994 Nov; 17(3):258-65. PubMed ID: 7851161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical demonstration of the KI-67-antigen in paraffin-embedded tumor biopsies.
    Böker DK; Stark HJ; Gullotta F; Nadstawek J; Schultheiss R
    Clin Neuropathol; 1990; 9(1):51-4. PubMed ID: 2306891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cell proliferation in colorectal adenomas containing invasive carcinoma.
    Risio M; Rossini FP
    Anticancer Res; 1993; 13(1):43-7. PubMed ID: 8097391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.